Use of PRP in Endometrial Reconstruction

Endometrial Reconstruction by Human Regenerative Factors Derived From Platelet-Rich Plasma in Mice Models

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03249415

Enrollment

Registered

2017-08-15

Start date

2017-07-18

Completion date

2023-12-31

Last updated

2025-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asherman Syndrome, Endometrial Atrophy

Keywords

Platelet-Rich Plasma, Cell therapy, Regenerative factors, Autologous treatment, Paracrine factors

Brief summary

Infertility, which affected 48.5 million couples worldwide in 2010 alone, has many causes; some causes result from issues related to the endometrium. Unfortunately, no cure exists for medical conditions resulting in the destruction of the endometrium, or for non-functional uterus. Thus, safe and effective therapies are needed to treat these diseases and to establish fertility in affected women. These novel techniques refer to the use and application of regenerative/paracrine factors to regenerate the endometrium in patients with Asherman's Syndrome (AS) and Endometrial Atrophy (EA).These new therapies based on the injection of the identified regenerative/paracrine factors and the platelet-rich plasma (PRP) from whole blood in an immunodeficient mouse model with AS/EA, evaluating their contribution and/or effect in the endometrial repair by functional proofs.

Detailed description

The objective is to know the effect of these regenerative factors obtained from Platelet-Rich Plasma in an immunodeficient murine model with AS/EA Blood from patients with Asherman's Syndrome (AS) and Endometrial Atrophy (EA) will be collected, maintained under anticoagulant solution and after several centrifugations PRP will be obtained. Demonstration of a functional endometrium will be proved determining pregnancy and implantation rates as well as the number of live pups/pregnant female in our mice model. Also, the uterus histology will be analysed in treated and untreated mice

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

25 Years to 40 Years

Healthy volunteers

Inclusion criteria

* Participants diagnosed with Asherman Syndrome and Endometrial Atrophy by Hysteroscopy. * No pregnancy after hormonal treatment.

Exclusion criteria

* Psychiatric diseases.

Design outcomes

Primary

Measure	Time frame	Description
Endometrial thickness after reconstruction in murine model	through study completion, an average of 1 year	Using histological and functional technologies demonstration of regeneration ability of PRP

Countries

Spain

Outcome results